N Bahrami1,2,3,4, D Piccioni5, R Karunamuni6, Y-H Chang2, N White7,3,4, R Delfanti3, T M Seibert6, J A Hattangadi-Gluth6, A Dale4,5, N Farid3,5, C R McDonald7,2,3,4. 1. From the Center for Multimodal Imaging and Genetics (N.B., N.W., C.R.M.) nabahrami@ucsd.edu naeim.bahrami@gmail.com. 2. Department of Psychiatry (N.B., Y.-H.C., C.R.M.). 3. Department of Radiology (N.B., N.W., R.D., A.D., N.F., C.R.M.). 4. Multimodal Imaging Laboratory (N.B., N.W., A.D., C.R.M.). 5. Department of Neurosciences (D.P., A.D., N.F.). 6. Department of Radiation Medicine (R.K., T.M.S., J.A.H.-G.), University of California, San Diego, La Jolla, California. 7. From the Center for Multimodal Imaging and Genetics (N.B., N.W., C.R.M.).
Abstract
BACKGROUND AND PURPOSE: Treatment with bevacizumab is standard of care for recurrent high-grade gliomas; however, monitoring response to treatment following bevacizumab remains a challenge. The purpose of this study was to determine whether quantifying the sharpness of the fluid-attenuated inversion recovery hyperintense border using a measure derived from texture analysis-edge contrast-improves the evaluation of response to bevacizumab in patients with high-grade gliomas. MATERIALS AND METHODS: MRIs were evaluated in 33 patients with high-grade gliomas before and after the initiation of bevacizumab. Volumes of interest within the FLAIR hyperintense region were segmented. Edge contrast magnitude for each VOI was extracted using gradients of the 3D FLAIR images. Cox proportional hazards models were generated to determine the relationship between edge contrast and progression-free survival/overall survival using age and the extent of surgical resection as covariates. RESULTS: After bevacizumab, lower edge contrast of the FLAIR hyperintense region was associated with poorer progression-free survival (P = .009) and overall survival (P = .022) among patients with high-grade gliomas. Kaplan-Meier curves revealed that edge contrast cutoff significantly stratified patients for both progression-free survival (log-rank χ2 = 8.3, P = .003) and overall survival (log-rank χ2 = 5.5, P = .019). CONCLUSIONS: Texture analysis using edge contrast of the FLAIR hyperintense region may be an important predictive indicator in patients with high-grade gliomas following treatment with bevacizumab. Specifically, low FLAIR edge contrast may partially reflect areas of early tumor infiltration. This study adds to a growing body of literature proposing that quantifying features may be important for determining outcomes in patients with high-grade gliomas.
BACKGROUND AND PURPOSE: Treatment with bevacizumab is standard of care for recurrent high-grade gliomas; however, monitoring response to treatment following bevacizumab remains a challenge. The purpose of this study was to determine whether quantifying the sharpness of the fluid-attenuated inversion recovery hyperintense border using a measure derived from texture analysis-edge contrast-improves the evaluation of response to bevacizumab in patients with high-grade gliomas. MATERIALS AND METHODS: MRIs were evaluated in 33 patients with high-grade gliomas before and after the initiation of bevacizumab. Volumes of interest within the FLAIR hyperintense region were segmented. Edge contrast magnitude for each VOI was extracted using gradients of the 3D FLAIR images. Cox proportional hazards models were generated to determine the relationship between edge contrast and progression-free survival/overall survival using age and the extent of surgical resection as covariates. RESULTS: After bevacizumab, lower edge contrast of the FLAIR hyperintense region was associated with poorer progression-free survival (P = .009) and overall survival (P = .022) among patients with high-grade gliomas. Kaplan-Meier curves revealed that edge contrast cutoff significantly stratified patients for both progression-free survival (log-rank χ2 = 8.3, P = .003) and overall survival (log-rank χ2 = 5.5, P = .019). CONCLUSIONS: Texture analysis using edge contrast of the FLAIR hyperintense region may be an important predictive indicator in patients with high-grade gliomas following treatment with bevacizumab. Specifically, low FLAIR edge contrast may partially reflect areas of early tumor infiltration. This study adds to a growing body of literature proposing that quantifying features may be important for determining outcomes in patients with high-grade gliomas.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Deva Sanjeeva Jeyaretna; William T Curry; Tracy T Batchelor; Anat Stemmer-Rachamimov; Scott R Plotkin Journal: J Clin Oncol Date: 2010-12-13 Impact factor: 44.544
Authors: Jorge Jovicich; Silvester Czanner; Douglas Greve; Elizabeth Haley; Andre van der Kouwe; Randy Gollub; David Kennedy; Franz Schmitt; Gregory Brown; James Macfall; Bruce Fischl; Anders Dale Journal: Neuroimage Date: 2005-11-21 Impact factor: 6.556
Authors: Elke Hattingen; Alina Jurcoane; Keivan Daneshvar; Ulrich Pilatus; Michel Mittelbronn; Joachim P Steinbach; Oliver Bähr Journal: Neuro Oncol Date: 2013-08-07 Impact factor: 12.300
Authors: Martha Nowosielski; Benedikt Wiestler; Georg Goebel; Markus Hutterer; Heinz P Schlemmer; Günther Stockhammer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch Journal: Neurology Date: 2014-04-11 Impact factor: 9.910
Authors: Alexandre Carpentier; Roger J McNichols; R Jason Stafford; Jean-Pierre Guichard; Daniel Reizine; Suzette Delaloge; Eric Vicaut; Didier Payen; Ashok Gowda; Bernard George Journal: Lasers Surg Med Date: 2011-11-22 Impact factor: 4.025
Authors: Rachel L Delfanti; David E Piccioni; Jason Handwerker; Naeim Bahrami; AnithaPriya Krishnan; Roshan Karunamuni; Jona A Hattangadi-Gluth; Tyler M Seibert; Ashwin Srikant; Karra A Jones; Vivian S Snyder; Anders M Dale; Nathan S White; Carrie R McDonald; Nikdokht Farid Journal: J Neurooncol Date: 2017-09-04 Impact factor: 4.130
Authors: Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Paul S Mischel; Whitney B Pope Journal: Neuro Oncol Date: 2011-02-15 Impact factor: 12.300
Authors: Eudocia C Quant; Andrew D Norden; Jan Drappatz; Alona Muzikansky; Lisa Doherty; Debra Lafrankie; Abigail Ciampa; Santosh Kesari; Patrick Y Wen Journal: Neuro Oncol Date: 2009-03-30 Impact factor: 12.300
Authors: Naeim Bahrami; Stephen J Hartman; Yu-Hsuan Chang; Rachel Delfanti; Nathan S White; Roshan Karunamuni; Tyler M Seibert; Anders M Dale; Jona A Hattangadi-Gluth; David Piccioni; Nikdokht Farid; Carrie R McDonald Journal: J Neurooncol Date: 2018-06-02 Impact factor: 4.130